Quick Answer
Maze Therapeutics, Inc. reported Diluted EPS of $3.05 per share (loss) for fiscal year 2025.
Maze Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$3.05 | -344.0% |
| 2024 | $1.25 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.66 | +93.6% | +14.3% |
| June 30, 2025 | -$0.77 | -123.9% | +33.0% |
| March 31, 2025 | -$1.15 | +91.7% | +88.8% |
| September 30, 2024 | -$10.25 | — | -418.3% |
| June 30, 2024 | $3.22 | — | +123.1% |
| March 31, 2024 | -$13.91 | — | — |
- Maze Therapeutics, Inc. showed a decrease of -344.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2024–2025 period, Maze Therapeutics, Inc.’s diluted eps has declined by 344.0% (from $1.25 per share to $3.05 per share (loss)).
- The most recent figure is from Maze Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: